Oncology Institute Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Oncology Institute Inc is 7.08, ranking 52 out of 75 in the Healthcare Providers & Services industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 136.56M, representing a year-over-year increase of 36.70%, while its net profit experienced a year-over-year increase of 4.14%.
Key Metrics
The current valuation score of Oncology Institute Inc is 7.50, ranking 28 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is -4.12, which is -44495.91% below the recent high of 1827.96 and -72.03% above the recent low of -7.08.
The current earnings forecast score of Oncology Institute Inc is 8.50, ranking 11 out of 75 in the Healthcare Providers & Services industry. The average price target is 6.50, with a high of 8.00 and a low of 5.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Oncology Institute Inc is 6.83, ranking 38 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 3.92 and the support level at 1.86, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Oncology Institute Inc is 3.00, ranking 60 out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 40.37%, representing a quarter-over-quarter decrease of 4.98%. The largest institutional shareholder is The Vanguard, holding a total of 4.75M shares, representing 4.83% of shares outstanding, with 145.18% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Oncology Institute Inc is 3.74, ranking 55 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 0.20. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
